Villar Emmanuel, Boissonnat Pascale, Sebbag Laurent, Hendawy Achraf, Cahen Rémi, Trolliet Pierre, Labeeuw Michel, Ecochard René, Pouteil-Noble Claire
Department of Nephrology, Dialysis and Transplantation, Hospices Civils de Lyon, Lyon Sud Hospital, Claude Bernard University, France.
Nephrol Dial Transplant. 2007 May;22(5):1383-9. doi: 10.1093/ndt/gfl811. Epub 2007 Jan 31.
Chronic kidney disease (CKD) and end-stage renal failure (ESRF) are major complications after a heart transplant. The aim of this study is to compare survival in heart transplant (HT) vs non-heart transplant (non-HT) patients starting dialysis.
Survival was studied among the 539 newly dialysed patients between 1 January 1995 and 31 December 2005 in our Department. All patients were prospectively followed from the date of first dialysis up to death or 31 December 2005. Multivariate survival analysis adjusted on baseline characteristics was performed with the Cox model.
There were 21 HT patients and they were younger than non-HT patients at first dialysis: 58.6+/-11.6 vs 63.0+/-16.2 years (P=0.09). Calcineurin inhibitor nephrotoxicity was the main cause of ESRF in HT patients (47.6%). Crude 1, 3 and 5-year survival rates in HT and in non-HT patients were as follows: 76.2%, 57.1%, 28.6% and 79.1%, 58.7%, 46.7% (P=0.2). The adjusted hazard ratio of death in HT vs non-HT patients was 2.27 [1.33-3.87], P=0.003. Sudden death was the main cause of death in HT patients, in 33.3% vs 10.4% in non-HT patients (P=0.01). Five HT patients benefited from renal transplant. They were all alive at the end of the study period, while one patient among the 16 remaining on dialysis survived.
HT patients with CKD who reached ESRF have a poor outcome after starting dialysis in comparison with other ESRF patients. Improvement in renal function management in the case of CKD is needed in these patients and non-nephrotoxic immunosuppressive regimens have to be evaluated. Renal transplant should be the ESRF treatment of choice in HT patients.
慢性肾脏病(CKD)和终末期肾衰竭(ESRF)是心脏移植后的主要并发症。本研究旨在比较开始透析的心脏移植(HT)患者与非心脏移植(非HT)患者的生存率。
对1995年1月1日至2005年12月31日期间在我科新开始透析的539例患者的生存率进行研究。所有患者从首次透析之日起进行前瞻性随访,直至死亡或2005年12月31日。采用Cox模型对基线特征进行调整后进行多变量生存分析。
有21例HT患者,他们首次透析时比非HT患者年轻:58.6±11.6岁对63.0±16.2岁(P=0.09)。钙调神经磷酸酶抑制剂肾毒性是HT患者ESRF的主要原因(47.6%)。HT患者和非HT患者的1年、3年和5年粗生存率如下:76.2%、57.1%、28.6%和79.1%、58.7%、46.7%(P=0.2)。HT患者与非HT患者死亡的调整后风险比为2.27 [1.33 - 3.87],P=0.003。猝死是HT患者的主要死亡原因,在HT患者中占33.3%,而在非HT患者中占10.4%(P=0.01)。5例HT患者接受了肾移植。在研究期末他们均存活,而其余16例仍在透析的患者中有1例存活。
与其他ESRF患者相比,达到ESRF的CKD的HT患者开始透析后的预后较差。这些患者需要改善CKD情况下的肾功能管理,并且必须评估非肾毒性免疫抑制方案。肾移植应是HT患者ESRF的首选治疗方法。